Could calcitonin gene‐related peptide inhibitors prevent status epilepticus?
Epilepsia · 2026
DOI: 10.1002/epi.70436 ↗Kurz gefasst
Fachartikel in der Zeitschrift Epilepsia, 2026. Verfasst von Michael Nsaka und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Milton S. Hershey Medical Center, Penn State College of Medicine, Hershey, Pennsylvania, USA. Hauptthemen laut MEDLINE: Status Epilepticus, Calcitonin Gene-Related Peptide, Migraine Disorders. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Calcitonin gene‐related peptide (CGRP) inhibitors modulate pain and neuroinflammation, a recognized contributor to epileptogenesis and status epilepticus (SE). We examined the association between CGRP inhibitor use and SE hospitalization in epilepsy patients with comorbid migraine. Using TriNetX (130 healthcare organizations), we identified patients with epilepsy from May 2018 through May 2026, and propensity‐matched cohorts for age, sex, race, anti‐seizure medications (ASMs), migraine diagnosis, migraine treatments, and cognitive impairment. The primary outcome was SE occurrence. Following matching, 17 738 patients were on CGRP inhibitors and 18 594 were not. SE occurred in 427 (2.41%) and 860 (4.63%) patients, respectively. Mean age (±SD) was 48.4 ± 14.9 vs 48.9 ± 17.0 years. Risk difference was −2.2% (95% confidence interval [CI]: −2.6% to −1.8%, p < .001), risk ratio 0.52 (95% CI: 0.46–0.58), and odds ratio 0.51 (95% CI: 0.45–0.57). SE‐related hospital visits were significantly fewer in the CGRP inhibitor group ( t = −6.60, p < .001). CGRP inhibitor use was associated with reduced SE occurrence and hospitalization, supporting further investigation in patients with comorbid migraine and epilepsy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Milton S. Hershey Medical Center, Penn State College of Medicine, Hershey, Pennsylvania, USA.
- Department of Neurology and Centre for Translational Neuro- and Behavioral Sciences (C-TNBS), West German Headache Centre, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
- Drexel University College of Medicine, Philadelphia, Pennsylvania, USA.
- Department of Public Health Sciences, A210, Penn State College of Medicine, Hershey, Pennsylvania, USA.
ORCID-Profile: Michael Nsaka, Armin Scheffler, Dagny Holle, Alain Lekoubou
Zitieren
APA
Nsaka, M., Baban, N., Allahdadian, S., Scheffler, A., Lindner, D., Holle, D., & Lekoubou, A. (2026). Could calcitonin gene‐related peptide inhibitors prevent status epilepticus?. Epilepsia. https://doi.org/10.1002/epi.70436
Vancouver
Nsaka M, Baban N, Allahdadian S, Scheffler A, Lindner D, Holle D, et al. Could calcitonin gene‐related peptide inhibitors prevent status epilepticus?. Epilepsia. 2026. doi:10.1002/epi.70436
BibTeX
@article{Nsaka2026,
author = {Nsaka, Michael and Baban, Noor and Allahdadian, Sepideh and Scheffler, Armin and Lindner, Diana and Holle, Dagny and Lekoubou, Alain},
title = {Could calcitonin gene‐related peptide inhibitors prevent status epilepticus?},
journal = {Epilepsia},
year = {2026},
doi = {10.1002/epi.70436}
}
EUVIMED